30 Years On, Are We Winning the Fight Against Alzheimer’s?

Lecanemab, Donanemab, Drug-Free Strategies Emerge as New Weapons Against Dementia By Suzanne Leigh UC San Francisco experts say that we have reached a pivotal point in Alzheimer’s disease research, 30 years after the first pharmaceutical came to market. On Jan. 6, 2023, the Food and Drug Administration is expected to give accelerated approval of lecanemab – one of the first drugs to attract widespread enthusiasm among neurologists, after showing positive phase 3 results in slowing the progression of early-stage disease. The UCSF-tested drug is a monoclonal antibody, a lab-made protein, that targets amyloid plaques that accumulate between neurons and disrupt

A-LIST Pulse of the Community Vol 14, December 2022

The mission of the A-LIST is to use survey results to make life better for the broader Alzheimer’s and dementia community. UsAgainstAlzheimer’s makes sure policymakers, researchers, healthcare providers, drug developers, insurers and others who serve this community understand and consider A-LIST member insights about the Alzheimer’s and dementia journey when making decisions that affect those living with the disease and caregivers. Read the full newsletter here.

Letter from Leading Alz Researchers: Journal “overstates and distorts” influence of flawed 2016 study

In a letter to the editor published in Science responding to the journal’s recent article on the apparent manipulation of data in a 2006 study of amyloid-β, two respected Alzheimer’s researchers state that the piece “overstates and distorts the effect of this paper on the Alzheimer’s field” and “does not threaten the ‘reigning theory’ of Alzheimer’s pathobiology, known as the ‘amyloid hypothesis’. The authors—Drs. Dennis Selkoe, The Vincent and Stella Coates Professor of Neurologic Diseases Harvard Medical School and Jeffrey Cummings, Director of the Chambers-Grundy Center for Transformative Neuroscience at UNLV—explain how the data in question is not a factor

A-LIST Pulse of the Community Vol 12, August 2022

The mission of the A-LIST is to leverage data to make life better for the Alzheimer’s and dementia community. UsAgainstAlzheimer’s shares our findings with policymakers, researchers, health care providers, public health officials, drug developers, insurers and others who serve this community to ensure they consider these insights when making decisions affecting people living with the disease and their caregivers. Read the full newsletter here.

A-LIST Pulse of the Community Vol 11, May 2022

The mission of the A-LIST is to use survey results to make life better for the broader Alzheimer’s andbdementia community.